R&D expense · 2019–2025
Pharming Group R&D expense
$100M+20.7% · FY2025
Pharming Group (PHAR) reported $100M in R&D expense for fiscal 2025, +20.7% year on year.
| Fiscal year | R&D expense | Change | Filing |
|---|---|---|---|
| FY20252025-12-31 | $100M | +20.7% | Open → |
| FY20242024-12-31 | $83.1M | +20.7% | Open → |
| FY20232023-12-31 | $68.9M | +31.2% | Open → |
| FY20222022-12-31 | $52.5M | −25.3% | Open → |
| FY20212021-12-31 | $70.4M | +82.7% | Open → |
| FY20202020-12-31 | $38.5M | +21.2% | Open → |
| FY20192019-12-31 | $31.8M | — | Open → |
R&D expense — Research and development expense is what the company charged to R&D in the income statement for the year. Most companies report no R&D at all — the line is absent rather than zero — so this ranking covers the roughly 40% of filers that do.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2019–2025 compound annual growth +21.1%
Figures are reported under IFRS, in US dollars.
R&D expense at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Pharming Group R&D expense |url=https://companiesranked.com/en/company/pharming-group/research-and-development-expense |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Pharming Group R&D expense. CompaniesRanked. https://companiesranked.com/en/company/pharming-group/research-and-development-expenseBibTeX
@misc{companiesranked-en-company-pharming-group-research-and-development-expense-2026,
author = {{CompaniesRanked}},
title = {{Pharming Group R\&D expense}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/pharming-group/research-and-development-expense}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 20-F · 0001828316-26-000015 · April 2, 2026
{{cite web |title=Pharming Group R&D expense — 20-F (0001828316-26-000015) |url=https://www.sec.gov/Archives/edgar/data/1828316/000182831626000015/pharm-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-04-02}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.